BPC-157 vs TB-500
Two compounds from the BPC / TB Series, side by side: how each one is built, the real chemistry that sets them apart, and why the two are so often kept together on the bench as a complementary research pair.
For laboratory and research use only. The rows above describe chemistry, methods, and handling, not efficacy or any human or veterinary use. Batch documentation is available on request.
What they share
BPC-157 and TB-500 are catalogued together in the BPC / TB Series, and on the bench they behave like close relatives. Both are short, linear research peptides built by Fmoc solid-phase peptide synthesis, where the chain is assembled one residue at a time on a resin, then cleaved, purified, and freeze-dried into a lyophilized powder.
Both are handled the same way as reference standards. Identity and purity are established with reverse-phase HPLC for the purity profile and mass spectrometry to confirm the molecular weight, and both are kept cold, dry, and dark to preserve a stable standard. Documentation describing how each batch was characterized is available on request rather than printed as a headline figure.
How they differ
The real difference is where each sequence comes from. BPC-157 is a 15-residue peptide, a synthetic partial sequence derived from a gastric protein. It does not exist as a standalone molecule in nature; it is a defined fragment chosen and made for research.
TB-500 is shorter and comes from a different parent. It is the 7-residue actin-binding region of thymosin beta-4, a naturally occurring regulatory protein. Where BPC-157 represents a slice of a gastric protein, TB-500 represents the specific stretch of thymosin beta-4 that interacts with actin in the cytoskeleton.
So although they sit in the same series and are made and verified the same way, they are chemically distinct molecules: different parent proteins, different sequences, and different lengths. The shared "BPC / TB" grouping is a cataloguing convention, not a statement that the two peptides are structurally related.
Why labs keep both
Rather than treating these as an either-or choice, the research literature tends to study BPC-157 and TB-500 as a pair, and many labs keep both on the bench at once. Because the two are chemically distinct, with different parent proteins, different sequences, and different lengths, they serve as complementary reference points: one anchored to a gastric-protein-derived sequence, the other to the actin-binding region of thymosin beta-4. Holding both gives a workspace two well-defined standards from the same series side by side.
Keeping both together is also practical. The two are interchangeable in workflow terms: both are lyophilized peptides characterized by RP-HPLC and mass spectrometry and stored cold, dry, and dark, so a method built around one transfers cleanly to the other and the pair shares the same handling and documentation. None of this implies any combined effect or use; it simply reflects how often the two are catalogued, stored, and referenced together as standards. Details of how identity is confirmed live in our documentation guide.
A complementary pair, commonly held together.
In the literature the two are frequently studied side by side, and many labs keep both on the bench at once.
Their different sequences and parent proteins make them complementary standards rather than substitutes.
BPC-157 derives from a gastric protein; TB-500 is the actin-binding region of thymosin beta-4.
Both are Fmoc-SPPS peptides, verified by RP-HPLC and MS, stored cold, dry, and dark.
BPC-157 vs TB-500
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-residue peptide (a pentadecapeptide), a synthetic partial sequence derived from a gastric protein. TB-500 is a shorter 7-residue peptide corresponding to the actin-binding region of thymosin beta-4. They come from different parent proteins and differ in sequence and length, even though both are catalogued in the same BPC / TB Series.
Should I keep both BPC-157 and TB-500?
In the research literature these two are frequently studied as a pair, and many labs keep both on the bench as reference standards. Their different sequences and parent proteins make them complementary reference points, so it is common to hold both rather than choosing one over the other. This is a cataloguing and reference-standard convention only and says nothing about efficacy or use. You can read each compound's full chemistry in the BPC-157 and TB-500 overviews.
How are BPC-157 and TB-500 synthesized?
Both are produced by Fmoc solid-phase peptide synthesis (SPPS), assembled residue by residue on a resin, then cleaved, purified, and lyophilized. Identity and purity are established with reverse-phase HPLC alongside mass spectrometry, as described in our standards and verification overview.
Are BPC-157 and TB-500 for research use only?
Yes. Both are supplied as reference standards for laboratory and research use only. They are not for human or veterinary consumption, and buyers are responsible for compliance with all applicable laws and regulations.